Atazanavir-ritonavir

Developed for: fibrotic liver disease · HIV infectious disease
Investigated by: CIHR Canadian HIV Trials Network · Fogarty International Center of the National Institute of Health · McGill University Health Centre/Research Institute of the McGill University Health Centre · Merck Sharp & Dohme LLC · NIH Office of AIDS Research (OAR) · National Institute of Neurological Disorders and Stroke (NINDS)
+1 more
· National Institute on Minority Health and Health Disparities (NIMHD)

today NCT04531072 · Ph 4 NCT01231685 · Ph 2

2012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 21 trial
Phase 2	NCT01231685	Dec 2011 → Mar 2016	HIV infectious disease, fibrotic liver disease, hepatitis C virus infection	McGill University Health Centre/Research Institute of the McGill University Health Centre	Completed	No outcome recorded
Phase 41 trial
Phase 4	NCT04531072	Sep 2018 → May 2019	—	Fogarty International Center of the National Institute of Health	Completed	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Atazanavir-ritonavir	“Atazanavir-ritonavir” NCT01231685 ↗ 1 NCT04531072 ↗